Tofflon Science and Technology Group Co., Ltd. announced that it has received CNY 2.4684 billion in funding from Nuode Asset Management Co., Ltd., Caitong Fund Management Co., Ltd., Shanghai Healthcare Capital Partnership (Limited Partnership), Shanghai Gaoyi Asset Management Partnership Enterprise (Limited Partnership), Guotou China Merchant Investment Management Co., Ltd.

On December 27, 2022, Tofflon Science and Technology Group Co., Ltd. closed the transaction. The company will now issue 120,000,000 A shares at an issue price of CNY 20.57 for the gross proceeds of CNY 2,468,400,000.00. The transaction included participation from Advanced Manufacturing Industry Investment Fund Phase II (Limited Partnership) for 24,307,243 shares for CNY 499,999,988.51, Shanghai Biomedical Industry Equity Investment Fund Partnership (Limited Partnership) for 24,307,243 shares for CNY 499,999,988.51, Shanghai Biomedical Industry Equity Investment Fund Partnership (Limited Partnership) for 24,307,243 shares for CNY 499,999,988.51, Ningbo Junhe Tongxin Equity Investment Partnership (Limited Partnership) for 14,584,346 shares for CNY 299,999,997.22, Nuode Asset Management Co., Ltd. for 13,867,282 shares for CNY 285,249,990.74, Shanghai Gaoyi Asset Management Partnership (Limited Partnership)-Gaoyi Xiaofeng No.

2 Letter Fund for 13,612,056 shares for CNY 279,999,991.92, Caitong Fund Management Co., Ltd. for 10,848,326 shares for CNY 223,150,065.82, Guangzhou Yuekai Healthcare Equity Investment Partnership (Limited Partnership) for 9,722,897 shares for CNY 199,999,991.29 and Taikang Asset Management Co., Ltd.-Taikang Asset Juxin Stock Specialized Pension Products for 8,750,607 shares for CNY 179,999,985.99. The company disclosed the issue expenses for CNY 40,086,534.56.